180 related articles for article (PubMed ID: 12932638)
1. Molecular targeting of drug delivery systems to ovarian cancer by BH3 and LHRH peptides.
Dharap SS; Qiu B; Williams GC; Sinko P; Stein S; Minko T
J Control Release; 2003 Aug; 91(1-2):61-73. PubMed ID: 12932638
[TBL] [Abstract][Full Text] [Related]
2. Enhancing the anticancer efficacy of camptothecin using biotinylated poly(ethylene glycol) conjugates in sensitive and multidrug-resistant human ovarian carcinoma cells.
Minko T; Paranjpe PV; Qiu B; Lalloo A; Won R; Stein S; Sinko PJ
Cancer Chemother Pharmacol; 2002 Aug; 50(2):143-50. PubMed ID: 12172980
[TBL] [Abstract][Full Text] [Related]
3. Targeted proapoptotic LHRH-BH3 peptide.
Dharap SS; Minko T
Pharm Res; 2003 Jun; 20(6):889-96. PubMed ID: 12817893
[TBL] [Abstract][Full Text] [Related]
4. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy.
Dharap SS; Chandna P; Wang Y; Khandare JJ; Qiu B; Stein S; Minko T
J Pharmacol Exp Ther; 2006 Mar; 316(3):992-8. PubMed ID: 16291730
[TBL] [Abstract][Full Text] [Related]
5. Targeted proapoptotic anticancer drug delivery system.
Chandna P; Saad M; Wang Y; Ber E; Khandare J; Vetcher AA; Soldatenkov VA; Minko T
Mol Pharm; 2007; 4(5):668-78. PubMed ID: 17685579
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo.
Yu D; Peng P; Dharap SS; Wang Y; Mehlig M; Chandna P; Zhao H; Filpula D; Yang K; Borowski V; Borchard G; Zhang Z; Minko T
J Control Release; 2005 Dec; 110(1):90-102. PubMed ID: 16271793
[TBL] [Abstract][Full Text] [Related]
7. Enhancing the efficacy of chemotherapeutic drugs by the suppression of antiapoptotic cellular defense.
Minko T; Dharap SS; Fabbricatore AT
Cancer Detect Prev; 2003; 27(3):193-202. PubMed ID: 12787726
[TBL] [Abstract][Full Text] [Related]
8. Folate-decorated and reduction-sensitive micelles assembled from amphiphilic polymer-camptothecin conjugates for intracellular drug delivery.
Liu C; Yuan J; Luo X; Chen M; Chen Z; Zhao Y; Li X
Mol Pharm; 2014 Nov; 11(11):4258-69. PubMed ID: 25238329
[TBL] [Abstract][Full Text] [Related]
9. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11.
Ray S; Almasan A
Cancer Res; 2003 Aug; 63(15):4713-23. PubMed ID: 12907654
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of gastric cancer by camptothecin involves apoptosis and multiple cellular pathways.
Litvak DA; Papaconstantinou HT; Hwang KO; Kim M; Evers BM; Townsend CM
Surgery; 1999 Aug; 126(2):223-30. PubMed ID: 10455888
[TBL] [Abstract][Full Text] [Related]
11. Amphiphilic star PEG-Camptothecin conjugates for intracellular targeting.
Omar R; Bardoogo YL; Corem-Salkmon E; Mizrahi B
J Control Release; 2017 Jul; 257():76-83. PubMed ID: 27677603
[TBL] [Abstract][Full Text] [Related]
12. Multifunctional tumor-targeted polymer-peptide-drug delivery system for treatment of primary and metastatic cancers.
Chandna P; Khandare JJ; Ber E; Rodriguez-Rodriguez L; Minko T
Pharm Res; 2010 Nov; 27(11):2296-306. PubMed ID: 20700631
[TBL] [Abstract][Full Text] [Related]
13. Enhanced anti-hepatocarcinoma efficacy by GLUT1 targeting and cellular microenvironment-responsive PAMAM-camptothecin conjugate.
Ma P; Sun Y; Chen J; Li H; Zhu H; Gao X; Bi X; Zhang Y
Drug Deliv; 2018 Nov; 25(1):153-165. PubMed ID: 29282992
[TBL] [Abstract][Full Text] [Related]
14. Internalization of cytotoxic analog AN-152 of luteinizing hormone-releasing hormone induces apoptosis in human endometrial and ovarian cancer cell lines independent of multidrug resistance-1 (MDR-1) system.
Günthert AR; Gründker C; Bongertz T; Schlott T; Nagy A; Schally AV; Emons G
Am J Obstet Gynecol; 2004 Oct; 191(4):1164-72. PubMed ID: 15507937
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor efficacy of redox and pH dually responsive micelleplexes for co-delivery of camptothecin and genes.
Chen M; Zhang Y; Chen Z; Xie S; Luo X; Li X
Acta Biomater; 2017 Feb; 49():444-455. PubMed ID: 27940163
[TBL] [Abstract][Full Text] [Related]
16. Tumor-targeted bioconjugate based delivery of camptothecin: design, synthesis and in vitro evaluation.
Paranjpe PV; Chen Y; Kholodovych V; Welsh W; Stein S; Sinko PJ
J Control Release; 2004 Nov; 100(2):275-92. PubMed ID: 15544875
[TBL] [Abstract][Full Text] [Related]
17. Camptothecin induces apoptosis in cancer cells via microRNA-125b-mediated mitochondrial pathways.
Zeng CW; Zhang XJ; Lin KY; Ye H; Feng SY; Zhang H; Chen YQ
Mol Pharmacol; 2012 Apr; 81(4):578-86. PubMed ID: 22252650
[TBL] [Abstract][Full Text] [Related]
18. Mixed micelles made of poly(ethylene glycol)-phosphatidylethanolamine conjugate and d-alpha-tocopheryl polyethylene glycol 1000 succinate as pharmaceutical nanocarriers for camptothecin.
Mu L; Elbayoumi TA; Torchilin VP
Int J Pharm; 2005 Dec; 306(1-2):142-9. PubMed ID: 16242875
[TBL] [Abstract][Full Text] [Related]
19. Differential GADD45, p21CIP1/WAF1, MCL-1 and topoisomerase II gene induction and secondary DNA fragmentation after camptothecin-induced DNA damage in two mutant p53 human colon cancer cell lines.
Goldwasser F; Bae I; Fornace AJ; Pommier Y
Oncol Res; 1996; 8(7-8):317-23. PubMed ID: 8938795
[TBL] [Abstract][Full Text] [Related]
20. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Chen TC; Su S; Fry D; Liebes L
Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
